---
title: "Eli Lilly’s Orforglipron Shows Superior Results in Diabetes Trial"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/257762299.md"
description: "Eli Lilly’s Phase 3 trial for orforglipron, an oral GLP-1 treatment for type 2 diabetes, showed superior results in reducing HbA1c levels and promoting weight loss compared to oral semaglutide. This positions Eli Lilly favorably in the diabetes market, though it won't affect Chugai Pharmaceutical's 2025 financial forecast. Chugai's stock (JP:4519) has a Buy rating with a price target of Yen7186.00, and the company focuses on innovative drug development in oncology, immunology, and diabetes."
datetime: "2025-09-17T14:53:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/257762299.md)
  - [en](https://longbridge.com/en/news/257762299.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/257762299.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/257762299.md) | [繁體中文](https://longbridge.com/zh-HK/news/257762299.md)


# Eli Lilly’s Orforglipron Shows Superior Results in Diabetes Trial

Chugai Pharmaceutical Co ( (JP:4519) ) just unveiled an update.

Chugai Pharmaceutical Co., Ltd. announced that Eli Lilly’s Phase 3 clinical trial results for orforglipron, an oral GLP-1 treatment for type 2 diabetes, showed superior efficacy in reducing HbA1c levels and promoting weight loss compared to oral semaglutide. The trial results, which demonstrated significant improvements in glycemic control and weight management, are expected to bolster Eli Lilly’s position in the diabetes treatment market, although they will not impact Chugai’s financial forecast for 2025.

The most recent analyst rating on (JP:4519) stock is a Buy with a Yen7186.00 price target. To see the full list of analyst forecasts on Chugai Pharmaceutical Co stock, see the JP:4519 Stock Forecast page.

**More about Chugai Pharmaceutical Co**

Chugai Pharmaceutical Co., Ltd. is a prominent player in the pharmaceutical industry, focusing on the development and marketing of innovative drugs. The company is known for its contributions to the healthcare sector, particularly in the areas of oncology, immunology, and diabetes treatment.

**Average Trading Volume:** 3,197,859

**Technical Sentiment Signal:** Buy

**Current Market Cap:** Yen11014.9B

For a thorough assessment of 4519 stock, go to TipRanks’ Stock Analysis page.

### Related Stocks

- [Eli Lilly and Company (LLY.US)](https://longbridge.com/en/quote/LLY.US.md)

## Related News & Research

- [FDA approves Eli Lilly's GLP-1 pill, opening the next phase of the weight loss drug market](https://longbridge.com/en/news/281394441.md)
- [FACTBOX-Pricing and availability of Novo, Lilly's weight-loss drugs](https://longbridge.com/en/news/281413480.md)
- [Here's How Much $100 Invested In abrdn Physical Silver Shares ETF 10 Years Ago Would Be Worth Today](https://longbridge.com/en/news/281394387.md)
- [Destiny Tech100 Stock Rises After SpaceX IPO Rumors](https://longbridge.com/en/news/281415250.md)
- [BREAKINGVIEWS-SpaceX IPO will gauge market moxie more than depth](https://longbridge.com/en/news/281406751.md)